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Background: Epilepsy is common in patients with a glioma. Antiepileptic drugs (AEDs) are the mainstay of epilepsy
treatment, but may cause side effects and may negatively impact neurocognitive functioning and quality of life. Besides
antiepileptic drugs, anti-tumour treatment, which currently consists of surgery, radiotherapy and/or chemotherapy, may
contribute to seizure control as well. In glioma patients with seizure freedom after anti-tumour therapy the question
emerges whether AEDs should be continued, particularly in the case where anti-tumour treatment has been successful.
We propose to explore the possibility of AED withdrawal in glioma patients with long-term seizure freedom after
anti-tumour therapy and without signs of tumour progression.
Methods/Design: We initiate a prospective, observational study exploring the decision-making process on the
withdrawal or continuation of AEDs in low-grade and anaplastic glioma patients with stable disease and prolonged
seizure freedom after anti-tumour treatment, and the effects of AED withdrawal or continuation on seizure freedom. We
recruit participants through the outpatient clinics of three tertiary referral centers for brain tumour patients in The
Netherlands. The patient and the treating physician make a shared decision to either withdraw or continue AED
treatment. Over a one-year period, we aim to include 100 glioma patients. We expect approximately half of the
participants to be willing to withdraw AEDs. The primary outcome measures are: 1) the outcome of the shared-decision
making on AED withdrawal or continuation, and decision related arguments, and 2) seizure freedom at 12 months and
24 months of follow-up. We will also evaluate seizure type and frequency in case of seizure recurrence, as well as
neurological symptoms, adverse effects related to AED treatment or withdrawal, other anti-tumour treatments and
tumour progression.
Discussion: This study addresses two issues that are currently unexplored. First, it will explore the willingness to withdraw
AEDs in glioma patients, and second, it will assess the risk of seizure recurrence in case AEDs are withdrawn in this
specific patient population. This study aims to contribute to a more tailored AED treatment, and prevent unnecessary and
potentially harmful use of AEDs in glioma patients.
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Epilepsy is common in patients with primary malignant
brain tumours, with incidence rates from 20 up to 90%, de-
pending on tumour type, the location of the tumour and its
proximity to the cortical gray matter [1-3]. The epilepto-
genicity of a tumour is inversely correlated with its growth
rate [4-6]. Low-grade gliomas (LGGs), and particularly
slow-growing tumours such as gangliogliomas and dysem-
bryoblastic neuroepithelial tumours (DNETs), are the most
epileptogenic [7-9]. A decrease in seizure frequency is
known to contribute to less morbidity and improved quality
of life [10,11]. Therefore, achieving sustained seizure con-
trol in these patients is an important issue in brain tumour
treatment.
Antiepileptic drugs (AEDs) are the mainstay of epi-
lepsy treatment. However, AEDs may cause side effects
and may also negatively impact neurocognitive function-
ing and quality of life [12]. Moreover, enzyme-inducing
AEDs may interfere with chemotherapeutic drugs and
corticosteroids and cause additional undesirable adverse
effects [1,13].
It is important to note that anti-tumour treatment,
which currently consists of surgery, radiotherapy and/or
chemotherapy, may contribute to seizure freedom as
well. Retrospective studies on seizure control after surgi-
cal resection report seizure freedom after 6–12 months
of follow-up in 63-75% of LGG patients [3,14-18]. In a
long-term follow-up study of patients with ganglio-
glioma of which 50% had refractory epilepsy, 85% re-
ported sustained seizure freedom after 5 years [19].
Similar effects on seizure control are observed after
radiotherapy or chemotherapy. In the EORTC phase III
trial comparing early versus late radiotherapy in LGG
patients, after radiotherapy 75% of patients were seizure
free, compared to 59% of patients who had not been ir-
radiated [20]. In several smaller series, after temozolo-
mide chemotherapy a more than 50% seizure reduction
was seen in 48-59% of LGG patients [21-26].
In patients with non-tumour-related epilepsy AEDs
are generally discontinued some time after successful
epilepsy surgery [18,27,28]. AED withdrawal following
temporal lobe resection in patients with refractory non-
tumoural epilepsy eventually leads to seizure freedom
without use of AEDs in 77% of patients [29]. In a review
on AED management after epilepsy surgery, AED with-
drawal was associated with a lower rate of seizure recur-
rence compared to AED continuation. Moreover, in 77%
of patients whose seizures recurred after AED with-
drawal, seizure freedom could be regained after restart
of medication [30]. After surgery for paediatric epilepsy,
seizure freedom was achieved in 77% of patients who
completed AED withdrawal during follow-up. Early AED
withdrawal did not affect long-term seizure outcome
[31]. In general, epileptologists recommend to starttapering after at least one year of seizure freedom after
epilepsy surgery, although the exact timing of AED with-
drawal is controversial [32-35].
In patients with seizure freedom after anti-tumour
therapy the question emerges whether AEDs should be
continued, particularly in the case where anti-tumour
treatment has been successful. In addition, several stud-
ies suggest that the efficacy of AEDs in brain tumour pa-
tients is limited. Up to 50% of brain tumour patients still
have seizures despite AED treatment [13,36].
Seizure frequency is likely to increase without AED
treatment in glioma patients with ongoing seizures, war-
ranting continued treatment. However, the necessity of
AEDs in glioma patients with long-term seizure control
is disputable. A few studies support the notion that seiz-
ure freedom in brain tumour patients can be maintained
without AEDs. In one series 45 out of 62 (73%) children
with a brain tumour whose AEDs were withdrawn after
anti-tumour treatment became seizure free [37]. Small
observational studies on AED use in meningioma and
LGG patients showed ongoing seizure freedom after
AED withdrawal in a majority of patients [38]. In case
seizures reoccur, they are often associated with tumour
recurrence [38]. Larger observational studies show that
AEDs often are unable to prevent seizure recurrence in
patients with renewed tumour growth [16].
Altogether, both studies on seizure freedom after anti-
tumour treatment and studies on seizure freedom after
epilepsy surgery suggest that an attempt to withdraw
AEDs is justified in glioma patients. Therefore, we
propose to explore the possibility of AED withdrawal in
low-grade and anaplastic glioma patients with long-term
seizure freedom after anti-tumour therapy and without
signs of tumour progression. As our study population
consists of a carefully selected group of glioma patients,
we aim to contribute to a more tailored AED treatment,
and prevent unnecessary and potentially harmful use of
AEDs in glioma patients.
Methods/Design
Design and overview
This is a prospective, observational study exploring the
decision-making process on the withdrawal or continu-
ation of AEDs in low-grade and anaplastic glioma pa-
tients with stable disease and prolonged seizure freedom
after anti-tumour treatment, and the effects of AED
withdrawal or continuation on seizure freedom. Over a
one-year period, we aim to include 100 glioma patients,
who will be followed for a duration of at least 24 months.
We primarily aim to improve current knowledge on the
patient’s and physician’s willingness to withdraw AEDs
in brain tumour patients, and to identify the rate of suc-
cessful AED withdrawals, i.e. that AED’s are withdrawn
completely without seizure recurrence. We hypothesize
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willing to withdraw AEDs, and 2) that there will be no
significant difference in seizure freedom at last follow-up
between patients who have withdrawn and those who
have continued their medication.
The study is approved by the institutional review




We recruit participants through the outpatient clinics of
three of the largest tertiary referral centers for brain tumour
patients in The Netherlands: one large community hospital
(Medical Center Haaglanden, The Hague) and two univer-
sity hospitals (VU University Medical Center, Amsterdam,
and Erasmus MC Cancer Institute, Rotterdam). The three
hospitals provide care for approximately one third of the
Dutch primary brain tumour population.
One of the co-investigators (JAFK and MK) will explore
which patients are potentially eligible for inclusion and
will maintain a log of every patient that has been
approached to participate. The logs contain the patient’s
initials, date of birth, date of screening, and whether the
patient has given informed consent, and if not, the reason
for non-participation. The co-investigator will inform the
treating neuro-oncologists on eligible patients in their out-
patients’ clinics. In case the treating neuro-oncologist
thinks that AED withdrawal in that particular patient
might have serious disadvantages (e.g. due to status epi-
lepticus in medical history, high co-morbidity with recur-
rent seizures), that patient will not be approached to
participate in the study, despite fulfillment of all eligibility
criteria. This will be recorded separately.
All eligible patients in whom the physician has no ser-
ious objections against AED withdrawal will receive a
patient information file. The treating neuro-oncologist
will provide additional information and answer ques-
tions. Patients who decide to participate will be asked to
give informed consent covering four topics: 1) to start
the shared decision-making process with their treating
physician on the withdrawal or continuation of AEDs
and to subsequently implement the joint decision, 2) to
collect relevant information from their medical records,
3) to follow-up their seizure status, where possible as a
part of the regular out-patient clinic appointments, and
4) to inform other medical specialists or the patient’s
general practitioner on the patient’s participation in the
study.
Eligibility criteria
Patients need to fulfill the following criteria to be included
in the study: 1) adult (>18 years); 2) histologically con-
firmed WHO grade I (pilocytic astrocytoma, pleomorphicxanthoastrocytoma, subependymal giant cell astrocytoma
or subependymoma), WHO grade II (astrocytoma, mixed
oligo-astrocytoma, oligodendroglioma or ependymoma),
or WHO grade III glioma (anaplastic astrocytoma, ana-
plastic oligodendroglioma, anaplastic oligo-astrocytoma or
anaplastic ependymoma); 3) history of epilepsy, defined as
the history of at least one seizure except for acute symp-
tomatic seizures, and treatment with AEDs; 4) having
undergone anti-tumour treatment (surgical resection,
brain irradiation and/or chemotherapy); 5) stable disease
with absence of clinical or radiological signs of tumour re-
currence, at least during the past 12 months; 6) seizure
freedom for at least 12 months from the date of last sur-
gery, irradiation or chemotherapy cycle, or seizure free-
dom for at least 24 months from the last seizure after the
last anti-tumour treatment.
Intervention
The patient and the treating physician make a shared deci-
sion on the preferred treatment (continuation or with-
drawal of AED). In case of deciding against the withdrawal
of AEDs, patient’s and/or physician’s reasons for continuing
are explicitly recorded. In case of deciding to withdraw,
AEDs are tapered according to a fixed schedule: a step-wise
50% dose reduction takes place every 2 weeks. The minim-
ally required reduction of total daily dose is as follows:
valproic acid: 250 mg; levetiracetam: 250 mg; carbamaze-
pine: 100 mg; oxcarbazepine: 150 mg; phenytoin: 50 mg;
clobazam: 2.5 mg; lamotrigine: 25 mg; topiramate: 25 mg;
clonazepam: 0.25 mg; and lacosamide: 50 mg. When the
patient uses 2 or more AEDs, the last add-on AED will be
withdrawn first and the primary AED (typically valproic
acid, levetiracetam or carbamazepine) will be withdrawn
thereafter.
Two groups of patients will be analysed, depending on
the outcome of the decision-making process: one group
consists of patients whose AEDs will be withdrawn, and
the other group consists of patients whose AEDs will be
continued. Standard follow-up in both groups takes
place after 3, 6, 12, 18 and 24 months. During follow-up,
data about AED treatment, including details on the
withdrawal where applicable, as well as data about seiz-
ure frequency and type, adverse effects, and clinical and
radiological brain tumour progression will be collected.
The study follow-up will be part of the regular follow-up
for those patients at the neuro-oncology outpatients’
clinic. In case of seizure recurrence, AEDs will be




After the patient has provided informed consent, we will
collect information on demographics, seizure onset, seizure
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dose, adverse effects, as well as data on past anti-tumour
treatments, tumour characteristics including histological
subtype and location, and neurological and radiological
findings.
Primary outcome measures
The two primary outcome measures are: 1) the outcome
of the shared-decision making on AED withdrawal or con-
tinuation, and decision related arguments, and 2) seizure
freedom at 12 months and 24 months of follow-up.
Secondary outcome measures
Secondary outcome measures are seizure type and fre-
quency in case of seizure recurrence, additional neuro-
logical symptoms, adverse effects related to AED treatment
or AED withdrawal, other anti-tumour treatments and
tumour progression. In case of tumour progression, the
time to clinical or radiological progression will be evaluated
as well. According to the response assessment in neuro-
oncology (RANO) criteria, clinical progression is defined as
a definite clinical deterioration that is not attributable to
other causes apart from the tumour or a decrease in cor-
ticosteroid dose. Radiological progression is defined as
a ≥25% increase in the area of the lesions on T2 or FLAIR
MRI, or the development of new lesions or increased or
new areas of enhancement [23,39].
At the last follow-up, patient’s decision to withdraw or
continue AEDs will be evaluated, using a study-specific
questionnaire on patient’s satisfaction with the decision.
Sample size
Based on the current population of patients with WHO
grade I-III glioma with epilepsy receiving treatment in one
of the three referral centers, we estimate that in one year a
total of 100 patients will be eligible for this study. The
number of patients who will actually withdraw their
AEDs, will depend on the outcome of the shared decision-
making process. Currently, there are no data on patients’
willingness to withdraw AEDs in this specific population.
A retrospective study showed that in 42% of patients with
intra-axial brain tumours AEDs were withdrawn after sur-
gery as part of routine clinical practice, although patients
on prophylactic AED treatment were also included in this
analysis [38]. A cautious estimate is that at least 30 per-
cent of the patients will be willing to withdraw AEDs. As
this is an observational study that is not primarily aimed
at exploring differences between the 2 groups, no formal
sample size calculation can be made. A total number of
100 patients, with at least 30 patients in each group,
should be sufficient to complete a prediction model, using
3 co-variates. We expect that less than 5% of the eligible




Baseline patient characteristics and information about
seizure freedom and seizure recurrence, AED treatment
and withdrawal, tumour symptoms, tumour recurrence
and additional anti-tumour treatments will be outlined
by means of descriptive statistics.
Univariate analysis
With logistic regression analysis, univariate variables (such
as age, gender, treatment, seizure type etc.) showing an as-
sociation (p < 0.10) with the decision to withdraw AEDs
will be identified, as well as univariate variables showing
an association (p < 0.10) with seizure recurrence.
Multivariable analysis
Next, a multivariable logistic regression analysis will be per-
formed to identify independent predictors of the decision
to withdraw AEDs. All variables that are univariately associ-
ated with this outcome measure will be entered as possible
predictors in a multivariable logistic regression analysis.
With a backward selection procedure, using a p-value of
0.10 as the removal criterion, significant independent pre-
dictors will be identified. Moreover, we will determine pre-
dictors of seizure recurrence. A similar analysis will be
performed with seizure recurrence as dependent outcome
variable. Variables (such as tumour location, pre-operative
seizure frequency, response on MRI, etc.) will be entered as
possible predictors in both multivariable logistic regression
analyses, using the aforementioned criteria. Note that this
analysis can only be performed in case of enough statistical
power.
Interim analysis
The co-investigators (JAFK and MK) will perform an in-
terim analysis when 20 patients who have withdrawn their
AEDs have reached at least 12 months of follow-up. The
aim of this interim analysis is to evaluate the effect of
AED withdrawal on seizure recurrence. In case ≥ 15 pa-
tients develop seizure recurrence within 12 months after
AED withdrawal, independent of tumour recurrence, we
consider the risk of seizure recurrence unacceptably high
and the study will be early terminated. The study will also
be ended when none of the first 20 included patients is
prepared to withdraw AED treatment.
Discussion
In this report, we describe the design of a prospective, ob-
servational study on the withdrawal of AEDs in low-grade
and anaplastic glioma patients with prolonged seizure free-
dom. This study addresses two issues that are currently
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AEDs in glioma patients, and second, it will assess the risk
of seizure recurrence in case in this specific patient popula-
tion AEDs are withdrawn. Furthermore, risk factors for
seizure recurrence including tumour progression will be
studied.
Given the lack of clear evidence on the feasibility of AED
withdrawal after anti-tumour treatment, there are – at this
stage – serious ethical objections to the randomisation of
patients. Moreover, in clinical practice most patients appear
to have strong personal preferences for either withdrawal
or continuation of AEDs. As a consequence, we have
chosen an observational non-randomised study design. Un-
like a randomised controlled study, the observational design
allows us to explore the decision-making process with re-
gard to AED treatment. As this study requires minimal
additional efforts from the participants, we expect that
most patients who are eligible for inclusion will be prepared
to provide informed consent. In addition, the limited num-
ber of eligibility criteria will result in a high external validity
of the study.
The participation of three of the largest referral cen-
ters for brain tumour patients contributes to the
strength of this study, as this allows us to reach a sub-
stantial part of all Dutch low-grade and anaplastic gli-
oma patients. As a consequence of the involvement of
patients in the decision-making process, this study is in
accordance with current clinical practice.
Based on previous studies on seizure status after anti-
tumour treatment or epilepsy surgery, we hypothesize
that AEDs can be safely withdrawn in glioma patients
who are seizure free and have shown no signs of tumour
recurrence. However, we acknowledge that in glioma pa-
tients there still is a risk of seizure recurrence, as the
epileptogenicity of the tumour may change over time,
in particular when the tumour starts growing again
[16,17,40,41]. To reduce the risk of seizure recurrence,
we will only include patients with clinically and radio-
logically stable disease and seizure freedom for at least
12 months after the last anti-tumour treatment. In
addition, we will include patients who experienced sei-
zures after anti-tumour treatment only after at least
24 months of seizure freedom. To ensure that patients
will not be subjected to an unacceptably high risk of sei-
zures, we will perform an interim analysis at the time
the first 20 study patients who have withdrawn AEDs
will have completed 12 months of follow-up. To prevent
excess numbers of patients to be unnecessarily exposed
to the intervention, the study will also end if none of the
first 20 patients who are included decide to withdraw
AEDs.
In summary, we present the design of a prospective
observational study aimed at the development of a more
targeted and well-considered AED treatment regimen inprimary brain tumour patients with epilepsy, and at pre-
venting possibly unnecessary treatment with AEDs. By
closely monitoring the decision-making process on AED
treatment and a subsequent observation of patient’s seiz-
ure status, we will gain more insight into both the will-
ingness of patients and the safety of withdrawing AEDs
in glioma patients with a presumably low risk of seizure
recurrence. As we expect that AED can be safely with-
drawn without substantially increasing the risk of seizure
recurrence, this study may lower patients’ and physi-
cians’ threshold to withdraw AEDs in glioma patients.
The results of this study may eventually guide future
recommendations concerning AED treatment in this
specific patient population.
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